Wednesday, July 8, 2026

pharma · Acne Vulgaris · Plasmodium Falciparum Malaria · ATXI

AVENUE THERAPEUTICS

AVENUE THERAPEUTICS clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bay Harbor Islands, USA HQ
10 Employees
Public company Type
ATXI · NYSE Ticker
Company details
Status
Public
HQ
Bay Harbor Islands, USA
Employees
10
Programs
4
Drugs
8
Patents
1
Intelligence · Clinical Programs

AVENUE THERAPEUTICS projects

4 ClinicalTrials.gov programs sponsored by AVENUE THERAPEUTICS.

AVENUE THERAPEUTICS has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Artemether-lumefantrine

    AVENUE THERAPEUTICS, INC.

    Plasmodium Falciparum Malaria

    phase 3 small molecule completed

    1 trial
  2. Tramadol

    AVENUE THERAPEUTICS, INC.

    Pain Management

    phase 3 small molecule active

    3 trials
  3. Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]

    AVENUE THERAPEUTICS, INC.

    Acne Vulgaris

    approved small molecule completed

    1 trial
  4. Pyridoxal-5'-Phosphate supplement

    AVENUE THERAPEUTICS, INC.

    Neural Inhibition

    small molecule active

    1 trial

Frequently asked questions

How many clinical projects does AVENUE THERAPEUTICS have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.